PMID- 31244444
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20200804
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 19
IP  - 3
DP  - 2019
TI  - CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia.
PG  - 195-204
LID - 10.2174/1871529X19666190627100613 [doi]
AB  - Leukemia is a group of progressive hematologic malignancies derived from stem 
      cells in bone marrow which causes a large number of cancer deaths. Even with 
      treatment such as traditional chemotherapy, targeted therapy, and allogeneic stem 
      cell transplantation (allo-HSCT), many patients suffer from relapse/refractory 
      disease, and the overall survival is dismal. Leukemic stem cells (LSCs) are 
      induced by gene mutations and undergo an aberrant and poorly regulated 
      proliferation process which is involved in the evolution, relapse, and 
      drug-resistance of leukemia. Emerging studies demonstrate that CD123, the 
      interleukin 3 receptor alpha (IL-3Ralpha), is highly expressed in LSCs, while not 
      normal hematopoietic stem cells (HSCs), and associates with treatment response, 
      minimal residual disease (MRD) detection and prognosis. Furthermore, CD123 is an 
      important marker for the identification and targeting of LSCs for refractory or 
      relapsed leukemia. Anti-CD123 target-therapies in pre-clinical studies and 
      clinical trials confirm the utility of anti-CD123 neutralizing antibody-drugs, 
      CD3xCD123 bispecific antibodies, dual-affinity retargeting (DART), and anti-CD123 
      chimeric antigen receptor-modified T-cell (CAR-T) therapies in progress. This 
      review summarizes the most recent progress on the study of CD123 biology and the 
      development of novel CD123-targeted therapies.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Shi, Mingyue
AU  - Shi M
AD  - Department of Pathology and Laboratory Medicine, UT Southwestern Medical Center, 
      Dallas, TX 75390, United States.
AD  - Department of Hematology, Henan Provincial People's Hospital & Zhengzhou 
      University People's Hospital, Henan, China.
FAU - Su, Ruijun J
AU  - Su RJ
AD  - Department of Pathology and Laboratory Medicine, University of California at Los 
      Angeles, Ronald Reagan UCLA Medical Center, Los Angeles, CA 90095, United States.
FAU - Parmar, Kamal-Preet
AU  - Parmar KP
AD  - Department of Pathology and Laboratory Medicine, UT Southwestern Medical Center, 
      Dallas, TX 75390, United States.
FAU - Chaudhry, Rahman
AU  - Chaudhry R
AD  - Department of Pathology and Laboratory Medicine, UT Southwestern Medical Center, 
      Dallas, TX 75390, United States.
FAU - Sun, Kai
AU  - Sun K
AD  - Department of Hematology, Henan Provincial People's Hospital & Zhengzhou 
      University People's Hospital, Henan, China.
FAU - Rao, Jianyu
AU  - Rao J
AD  - Department of Pathology and Laboratory Medicine, University of California at Los 
      Angeles, Ronald Reagan UCLA Medical Center, Los Angeles, CA 90095, United States.
FAU - Chen, Mingyi
AU  - Chen M
AD  - Department of Pathology and Laboratory Medicine, UT Southwestern Medical Center, 
      Dallas, TX 75390, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IL3RA protein, human)
RN  - 0 (Interleukin-3 Receptor alpha Subunit)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Biomarkers, Tumor/analysis/antagonists & inhibitors
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Interleukin-3 Receptor alpha Subunit/*analysis/antagonists & inhibitors
MH  - Leukemia/*diagnosis/*therapy
OTO - NOTNLM
OT  - CD123
OT  - LSCs
OT  - anti-CD123
OT  - hematologic malignant diseases
OT  - leukemia
OT  - refractory/relapse.
EDAT- 2019/06/28 06:00
MHDA- 2020/08/05 06:00
CRDT- 2019/06/28 06:00
PHST- 2018/09/24 00:00 [received]
PHST- 2019/03/20 00:00 [revised]
PHST- 2019/04/23 00:00 [accepted]
PHST- 2019/06/28 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2019/06/28 06:00 [entrez]
AID - CHDDT-EPUB-99241 [pii]
AID - 10.2174/1871529X19666190627100613 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2019;19(3):195-204. doi: 
      10.2174/1871529X19666190627100613.